indazoles has been researched along with Uterine Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Chao, A; Huang, HJ; Lai, CH; Lee, LY; Lee, YS; Lin, CY; Peng, MT; Tsai, CL; Ueng, SH; Wang, HS; Wu, RC; Yang, LY | 1 |
| Houchi, H; Kawakita, K; Kosaka, S; Kuroda, Y; Okazaki, T; Suzuki, K; Takahashi, K; Tanaka, H; Tatsumichi, T | 1 |
| Aiello, N; Barra, F; Bogani, G; Ditto, A; Ferrero, S; Leone Roberti Maggiore, U; Lorusso, D; Raspagliesi, F | 1 |
| Benson, C; Freivogel, KW; Gelderblom, H; Grignani, G; Jobanputra, M; Judson, IR; Katz, D; Manson, SC; Merimsky, O; Mungul, A; Sanfilippo, R; Stein, D | 1 |
| Kim, HJ; Kim, Y; Lee, J; Lee, SJ; Park, SH | 1 |
| Barra, F; De Cian, F; Di Domenico, S; Ferraioli, D; Ferrero, S; Tantari, M; Vellone, VG | 1 |
| Brady, WE; Campos, SM; DiSilvestro, PA; Hanjani, P; Hensley, ML; Lee, PS; Moxley, KM; O'Cearbhaill, RE; O'Malley, DM; Rose, PG; Rotmensch, J; Thaker, PH; Zuna, RE | 1 |
| Benson, C; Blay, JY; Chawla, S; Dewji, MR; Gil, T; Judson, I; Le Cesne, A; Litière, S; Marréaud, S; Papai, Z; Piperno-Neumann, S; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WTA | 1 |
| Ebina, Y; Miyamoto, T; Nagamata, S; Nishijima, M; Yamada, H; Yamano, Y | 1 |
| Fujiwara, K; Hasegawa, K; Kozawa, E; Nishikawa, T; Yabuno, A; Yasuda, M; Yoshida, H | 1 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Fukunaka, N; Ishioka, S; Itoh, E; Kitajima, Y; Kudo, R; Sagae, S; Sato, K | 1 |
3 review(s) available for indazoles and Uterine Neoplasms
| Article | Year |
|---|---|
Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Leiomyosarcoma; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Uterine Neoplasms | 2017 |
Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Combined Modality Therapy; Doxorubicin; Female; Humans; Indazoles; Leiomyosarcoma; Prognosis; Pyrimidines; Sulfonamides; Uterine Neoplasms | 2019 |
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
2 trial(s) available for indazoles and Uterine Neoplasms
| Article | Year |
|---|---|
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Aged; Angiogenesis Inhibitors; Carcinosarcoma; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2014 |
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Leiomyosarcoma; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Survival Rate; Uterine Neoplasms; Young Adult | 2016 |
8 other study(ies) available for indazoles and Uterine Neoplasms
| Article | Year |
|---|---|
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |
Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; CLOCK Proteins; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Hyperthermia, Induced; Indazoles; Leiomyosarcoma; Pyrimidines; Sulfonamides; Uterine Neoplasms | 2020 |
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Female; Humans; Indazoles; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sarcoma; Sulfonamides; Uterine Neoplasms | 2021 |
Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Topics: Angiogenesis Inhibitors; Compassionate Use Trials; Disease-Free Survival; Female; Hemangiosarcoma; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Solitary Fibrous Tumors; Sulfonamides; Survival Rate; Time Factors; Uterine Neoplasms | 2017 |
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Salvage Therapy; Sarcoma; Sulfonamides; Survival Analysis; Uterine Neoplasms | 2018 |
A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Topics: Antineoplastic Agents; Female; Humans; Indazoles; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed; Uterine Neoplasms | 2016 |
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.
Topics: Aged; Antineoplastic Agents; Carcinosarcoma; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Uterine Neoplasms | 2017 |
[The prevention of CDDP-induced emesis with granisetron].
Topics: Antiemetics; Cisplatin; Female; Granisetron; Humans; Indazoles; Infusions, Intravenous; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1993 |